Harvard bioscience, inc.
HBIO 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分優異，但股利評分未超過2分，若公司開始配息，可能會有更優異的投資結果
HBIO 近期報酬表現
-6.80%
Harvard bioscience, inc.
-0.89%
同產業平均
-0.88%
S&P500
與 HBIO 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
NMRA | Neumora therapeutics inc | - | 2 分 | 2 分 | 2 分 | 1 分 | |
KMDA | Kamada ltd | 3 分 | 2 分 | 2 分 | 1 分 | 1 分 | |
VKTX | Viking therapeutics inc | 4 分 | 3 分 | 3 分 | 2 分 | 1 分 | |
CERE | Cerevel therapeutics holdings inc | 3 分 | 3 分 | 1 分 | 4 分 | 1 分 | |
ATAI | Atai life sciences nv | - | 3 分 | 2 分 | 1 分 | 1 分 |
- NMRA Neumora therapeutics inc價值 -趨勢 2 分波段 2 分籌碼 2 分股利 1 分查看更多
HBIO 公司資訊
Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bioproduction and preclinical testing for pharmaceutical and therapy development. Its products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. The CMT product family is primarily composed of products supporting research related to molecular, cellular, organ and organoid technologies. The Preclinical product family includes products that support the preclinical research and testing phase for drug development, and in particular, testing related to data collection and analysis for safety and regulatory compliance.